Protein-protein interaction as biomarkers
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorEric B. Haura
Life of this patent
Estimating the term…
Abstract
The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.
Claims17
A method for treating a malignancy in a subject, comprising administering a protein-protein interaction (PPI) inhibitor or inducer to the subject, wherein the subject is predetermined to have two or more target binding partners of a cancer cell signaling network that are detected by proximity ligation assay (PLA), wherein the target binding partners are selected from among the following pairs of binding partners:
- epidermal growth factor receptor (EGFR) and Erb-B2 receptor tyrosine kinase 3 (ErbB3);
- EGFR and growth factor receptor-bound protein 2 (Grb2);
- EGFR and mitogen-inducible gene-6 (Mig6);
- EGFR and suppressor of T-cell receptor signalling 1 (Sts1);
- EGFR and proto-oncogene tyrosine-protein kinase Src (Src);
- EGFR and heat shock protein 90 (Hsp90);
- ErbB3 and phosphatidylinositol 3-kinase regulatory subunit p85 (p85);
- anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4);
- tyrosine-protein kinase Met (MET) and Grb2-associated binding protein 1 (Gab1);
- insulin-like growth factor receptor (IGFR) and insulin receptor substrate (IRS);
- Hsp90 and cell division cycle 37 (Cdc37);
- ALK and SHC adaptor protein 1 (Shc1);
- and EGFR and Shc1, and wherein the PPI inhibitor or inducer inhibits or induces protein-protein interaction between the two or more target binding partners.
A method for treating a malignancy in a subject, comprising:
- (a) measuring a protein-protein interaction (PPI) of a cancer signaling network using a proximity ligation assay (PLA) in a cancer cell sample obtained from the subject, wherein said measuring comprises measuring two or more target binding partners of the cancer signaling network, and wherein the target binding partners are selected from among the following pairs of binding partners:
- epidermal growth factor receptor (EGFR) and Erb-B2 receptor tyrosine kinase 3 (ErbB3);
- EGFR and growth factor receptor-bound protein 2 (Grb2);
- EGFR and mitogen-inducible gene-6 (Mig6);
- EGFR and suppressor of T-cell receptor signalling 1 (Sts1);
- EGFR and proto-oncogene tyrosine-protein kinase Src (Src);
- EGFR and heat shock protein 90 (Hsp90);
- ErbB3 and phosphatidylinositol 3-kinase regulatory subunit p85 (p85);
- anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4);
- tyrosine-protein kinase Met (MET) and Grb2-associated binding protein 1 (Gab1);
- insulin-like growth factor receptor (IGFR) and insulin receptor substrate (IRS);
- Hsp90 and cell division cycle 37 (Cdc37);
- ALK and SHC adaptor protein 1 (Shc1);
- and EGFR and Shc1;
- and
- (b) administering a PPI inhibitor or inducer to the subject, wherein the PPI inhibitor or inducer inhibits or induces protein-protein interaction between the two or more target binding partners.
Dependencies are inferred from the claim text.